Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608699 · ClinicalTrials.gov registry record · Phase 1
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00608699 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT00608699, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
Interventions
- DRUG GSK256073A tablets + IR niacin tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608699
The ClinicalTrials.gov registry entry for NCT00608699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK256073A tablets + IR niacin tablets is the first listed.
NCT00608699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608699 about?
NCT00608699 is a clinical study titled "A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers". To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
What is the current status of trial NCT00608699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00608699?
The interventions under investigation include: GSK256073A tablets + IR niacin tablets (DRUG).
Who is sponsoring clinical trial NCT00608699?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.